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Background: Familial combined hyperlipidemia (FCH) is a polygenic and multifactorial disease charac-
terized by a variable phenotype showing increased levels of triglycerides and/or cholesterol.
The aim of this study was to identify single nucleotides (SNPs) in lipid-related genes associated with FCH.
Methods and results: Twenty SNPs in lipid-related genes were studied in 142 control subjects and 165
FCH patients after excluding patients with mutations in the LDLR gene and patients with the E2/E2
genotype of APOE. In particular, we studied the 9996G > A (rs2073658) and 11235C > T (rs3737787)
variants in the Upstream Stimulatory Factor 1 gene (USF1), and the 1131T > C (rs662799) and S19W
(rs3135506) variants in the Apolipoprotein A-V gene (APOA5). We found that the frequencies of these
variants differed between patients and controls and that are associated with different lipid proﬁles. At
multivariate logistic regression SNP S19W in APOA5 remained signiﬁcantly associated with FCH inde-
pendently of age, sex, BMI, cholesterol and triglycerides.
Conclusions: Our results show that the USF1 and APOA5 polymorphisms are associated with FCH and
that the S19W SNP in the APOA5 gene is associated to the disease independently of total cholesterol,
triglycerides and BMI. However, more extensive studies including other SNPs such as rs2516839 in USF1,
are required.
© 2014 Elsevier Ltd. All rights reserved.1. Introduction
Familial combined hyperlipidemia (FCH) is the most frequent
familial dyslipidemia with a prevalence of 1% in the general pop-
ulation and 38% in young patients with myocardial infarct [1,2].
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nato@unina.it (G. Fortunato).variable lipid proﬁle over time and in the different members of the
affected families are the main characteristics of FCH [3]. These
characteristics make FCH diagnosis particularly difﬁcult due to its
overlapping with other metabolic diseases and to the variability of
its phenotype [4]. The presence of small dense LDLs (sdLDL) and
increased levels of Apolipoprotein B (ApoB) [5] have been consid-
ered hallmarks of FCH, although it has been recently demonstrated
that they are also common to other hyperlipidemias [5]. The genetic
background of FCH is heterogeneous as it includes many genes
having a different impact on the disease development [1]. Owing to
a partially overlapping phenotype, mutations in the LDL receptor
and Apo E genes usually causing other familial dyslipidemias, such
as familial hypercholesterolemia and dysbetalipoproteinemia, have
been equally identiﬁed in patients with a clinical diagnosis of FCH
[6,7]. In most of the previous association studies performed in FCH
populations including patients with different types of dyslipide-
mias, the impact of rare variants has lead to potentially
Table 1
Demographic, biochemical and clinical features of control subjects and FCH patients.
Parameter Controls n ¼ 142 FCH patients
n ¼ 165
Signiﬁcance
Age (years) 43.9 ± 9.6 47.5 ± 12.2 p ¼ 0.005
Gender (n males and %) 65 (46%) 121 (73%) p < 0.0001
BMI (kg/m2) 25.5 ± 4.1 27.2 ± 3.4 p < 0.0001
Triglycerides (mmol/L)a 0.88 (0.63e1.24) 2.28 (1.71e3.38) p < 0.0001
Total cholesterol (mmol/L) 4.85 ± 0.72 6.97 ± 1.39 p < 0.0001
LDL cholesterol (mmol/L) 3.08 ± 0.66 4.66 ± 1.35 p < 0.0001
HDL cholesterol (mmol/L) 1.30 ± 0.33 1.03 ± 0.30 p < 0.0001
Non-HDL cholesterol
(mmol/L)
3.54 ± 0.75 5.94 ± 1.35 p < 0.0001
ApoB (g/L) 0.88 ± 0.19 1.36 ± 0.30 p < 0.0001
ApoB/total
cholesterol (g/mmol)a
0.18 (0.17e0.20) 0.20 (0.18e0.21) p < 0.0001
LDL score (% sdLDL/LDL)a 1.34 (0e3.95)
n ¼ 128
20.5 (11.5e30.8)
n ¼ 80
p < 0.0001
LDL diameter (Å)a 272 (270e273)
n ¼ 128
263 (259e266)
n ¼ 80
p < 0.0001
Glucose (mmol/L)a 5.19 (4.83e5.49) 5.27 (4.94e5.88) p ¼ 0.001
C-reactive protein (mg/L)a 1.0 (0.6e2.1) 1.9 (1.0e3.5) p < 0.0001
Diabetes n (%) 1 (0.7%) 14 (8.5%) p ¼ 0.002
Obesity n (%) 22 (15.5%) 23 (13.9%) n.s.
Hypertension n (%) 1 (0.7%) 41 (24.8%) p < 0.0001
Metabolic syndrome n (%) 8 (6.7%) 111 (67.3%) p < 0.0001
Continuous variables with a parametric distribution are reported as
mean ± standard deviation.
n.s. Difference not statistically signiﬁcant.
a Data are reported as median and interquartile range (non-parametric
distribution).
Table 2
List of analyzed SNPs.
Gene
symbol
Full gene name Variant Position SNP ID
APOA5 Apolipoprotein A-V 1131T > C 50 Gene/
promoter
rs662799
S19W Coding rs3135506
APOC3 Apolipoprotein C-III 482T > C 50 gene/
promoter
rs2854117
2342 G > C 30 UTR rs5128
2373 G > T 30 UTR rs4225
LPL Lipoprotein lipase 280T > G 50 UTR rs1800590
D9N Coding rs1801177
N291S Coding rs268
S474X Coding rs328
HMGCR 3-hydroxy-3-
methylglutaryl-CoA
reductase
10173A > T Intronic rs12654264
12654A > G Intronic rs3846662
PCSK9 Proprotein convertase
subtilisin/kexin type 9
25467958T > C 50 Gene/
promoter
rs11206510
R46L Coding rs11591147
CETP Cholesteryl ester
transfer
protein, plasma
656C > A 50 Gene/
promoter
rs1800775
V405I Coding rs5882
R451Q Coding rs1800777
USF1 Upstream stimulatory
factor 1
9996G > A intronic rs2073658
11235C > T 30 UTR rs3737787
PPARG Peroxisome
proliferator-activated
receptor gamma
P12A Coding rs1801282
KIF6 Kinesin family
member 6
W719R Coding rs20455
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growing number of cardiovascular diseases, some Single nucleotide
polymorphisms (SNPs) in lipid-related genes have been studied for
their association with cardiovascular markers [8].
The aimof this paper is to perform an association study of 20 SNPs
in lipid-related genes in a well selected population of FCH patients.
The study was performed after excluding patients with mutations in
the LDLR gene or with the E2/E2 genotype of APOE since these vari-
ants could have an impact on the dyslipidemic phenotype.
2. Materials and methods
2.1. Studied population
One hundred sixty-ﬁve unrelated patients with FCH, among
those consecutively admitted to the outpatient Lipid Clinic of the
University of Naples, were enrolled in the study, after excluding
patients with secondary causes of dyslipidemia, patients with mu-
tations in the LDLR gene or with the E2/E2 genotype for APOE aswell
as patients taking any drug known to affect lipid metabolism. Ge-
netic screening of LDLR was performed as previously described [9],
whereas the analysis of the APOE polymorphisms was performed by
Real-Time PCR on Light Cycler (Roche, Mannheim, Germany), using
speciﬁc hybridization probes and subsequent melting curve analysis.
Familial combined hyperlipidemia was diagnosed according to
the criteria suggested by Gaddi et al. [4]: serum triglyceride levels
higher than 200 mg/dL (2.3 mmol/L) and/or LDL cholesterol higher
than 160mg/dL (4.1mmol/L) and/or ApoB higher than 130mg/dL in
the proband, plus phenotype variability in at least one ﬁrst-degree
relative. Exclusion criteria are related to a possible secondary dys-
lipidemia, i.e. thyroid dysfunction, renal or hepatic diseases.
Metabolic syndrome was diagnosed as previously described [10].
The features of FCH patients and the 142 healthy subjects from the
same ethno-geographic origin used as the reference population, are
reported in Table 1. The study was performed according to the
current version of the Helsinki Declaration. Informed consent was
obtained for each patient or control.
2.2. SNP genotyping
The selected SNPs were the most frequently associated with
lipidmetabolism alterations, such as hypertriglyceridemia, FCH and
metabolic syndrome.
SNPs listed in Table 2 were assayed, in duplicate, by the real time
TaqMan® method; primers and probes were chosen among pre-
developed assays or were taken from custom assays service of
Applied Biosystems. Real time PCR was performed as previously
described [11] on an ABI Prism 7900-HT instrument with the
Sequence Detection System 2.3 (Applied Biosystems, Foster City,
CA, USA).
2.3. Biochemical analysis
Biochemical markers were measured on serum after an over-
night fast. Total cholesterol, HDL cholesterol, triglyceride and
glucose levels were evaluated by standard methods using an
automated analyzer (Modular P3, Roche, Mannheim, Germany).
LDL cholesterol concentrations were calculated according to the
Friedewald method or measured using a homogeneous enzymatic
colorimetric assay if triglycerides levels were higher than 400 mg/
dL. ApoB and ultra sensitive C-reactive protein were measured on
serum (Dade-Behring, Marburg, Germany). LDL particles separation
was performed by Lipoprint System (Quantimetrix Inc., Redondo
Beach, CA, USA). The diameter of LDL particles at the cut-off point
separating subfractions 1e2 from subfractions 3e7 (sdLDL) was251 Å [12]. The proportion of sdLDL particles to the whole LDL area
was calculated in our sample (LDL score).2.4. Statistical analysis
Continuous variables were expressed as a mean ± SD (para-
metric distributions) or median value and interquartile range (non-
Table 3
Genotype and allele frequencies of SNPs in APOA5 and USF1 genes.
FCH patients Controls Signiﬁcance level
APOA5 1131T > C
Genotypes n ¼ 165 n ¼ 142
TT 111 (67.3%) 117 (82.4%) p ¼ 0.010
TC 49 (29.7%) 23 (16.2%)
CC 5 (3.0%) 2 (1.4%)
Dominant model for C allele
TT 111 (67.3%) 117 (82.4%) p ¼ 0.003
TC þ CC 54 (32.7%) 25 (17.6%)
Allele frequencies
Allele C 0.179 0.095 p ¼ 0.003
Allele T 0.821 0.905
APOA5 S19W
Genotypes n ¼ 165 n ¼ 142
SS 123 (74.5%) 125 (88.0%) p ¼ 0.008
SW 40 (24.2%) 17 (12.0%)
WW 2 (1.2%) 0
Dominant model for W allele
SS 123 (74.5%) 125 (88.0%) p ¼ 0.003
SW þ WW 42 (25.5%) 17 (12.0%)
Allele frequencies
Allele S 0.867 0.940 p ¼ 0.002
Allele W 0.133 0.060
USF1 9996G > A
Genotypes n ¼ 164 n ¼ 135
GG 103 (62.8%) 58 (43.0%) p ¼ 0.003
GA 53 (32.3%) 65 (48.1%)
AA 8 (4.9%) 12 (8.9%)
Dominant model for A allele
GG 103 (62.8%) 58 (43.0%) p ¼ 0.001
GA þ AA 61 (37.2%) 77 (57.0%)
Recessive model for A allele
GG þ GA 156 (95.1%) 123 (91.1%) p ¼ 0.167
AA 8 (4.9%) 12 (8.9%)
Allele frequencies
Allele G 0.790 0.670 p ¼ 0.001
Allele A 0.210 0.330
USF1 11235C > T
Genotypes n ¼ 164 n ¼ 135
CC 104 (63.4%) 58 (43.0%) p ¼ 0.002
CT 52 (31.7%) 65 (48.1%)
TT 8 (4.9%) 12 (8.9%)
Dominant model for T allele
CC 104 (63.4%) 58 (43.0%) p ¼ 0.001
CT þ TT 60 (36.6%) 77 (57.0%)
Recessive model for T allele
CC þ CT 156 (95.1%) 123 (91.1%) p ¼ 0.167
TT 8 (4.9%) 12 (8.9%)
Allele frequencies
Allele C 0.793 0.670 p ¼ 0.0007
Allele T 0.207 0.330
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number and percentage. KolmogoroveSmirnov test was performed
to assess the hypothesis of a normal distribution of variables. Dif-
ferences between groups were assessed by T-test, non-parametric
ManneWhitney test and chi-square test, as appropriate. Genotype
and allele frequencies were calculated by allele counting and de-
parture from Hardy-Weinberg expectation was evaluated by chi-
square analysis (all SNPs were in equilibrium). To test the type of
association, dominant and recessive models were constructed for
the rare allele of each polymorphism, and univariate odds ratio
(OR) with 95% Conﬁdence Interval (CI) were calculated. Multivar-
iate linear and logistic regressions were performed including
dominant models of SNPs (encoded as 1 ¼ homozygous common
allele and 2¼ rare allele carrier), gender (1¼ female and 2¼male),
age in years and Body Mass Index (BMI - kg/m2). Statistical analysis
was performed with PASW version 18.0 software (SPSS Inc., Chi-
cago, IL, USA). Haploview (www.broad.mit.edu/mpg/haploview)
3.2 software was used to calculate the differences of allele fre-
quencies, linkage disequilibrium (a D0, a normalized measure of
allelic association, equal or greater than 0.8 deﬁnes a positive as-
sociation). The plot of D0 for analyzed SNPs is reported in
Supplemental Fig. 1. A p value <0.05 was considered signiﬁcant. In
order to discriminate between FCH and healthy patients, multi-
variate logistic regression was also used as a classiﬁcation model
built on top of the most signiﬁcant predictors, namely the domi-
nant model of 1131T > C and S19W in APOA5, the 9996G > A in
USF1, Age, Gender, Triglycerides, Total cholesterol, and BMI. Since
data were not available for all patients, multivariate logistic
regression was performed on 157 FCH patients and 134 controls.
As a resampling method, a 200 run of 10-fold cross-validation
was performed and implemented in Matlab (www.mathworks.
com) to construct a ﬁtted model aimed at calculating the poste-
rior probabilities of developing FCH. The ROC curve and the area
under the ROC curve (AUC) were also computed with their proba-
bilities calculated from the ﬁtted model to assess the classiﬁer
performance and calculate accuracy, sensitivity and speciﬁcity. The
ROC curve is computed on the test data (the left-out data in each
fold from the cross-validation procedure) in order to show the
estimated proportion of FCH class subjects correctly classiﬁed as
class FCH against the estimated proportion of class healthy subjects
non classiﬁed as class FCH for different thresholds of the classiﬁer
output. This method allows to ﬁnd the threshold that maximizes
the classiﬁcation accuracy or to assess, in broad terms, how the
classiﬁer performs in the regions of high sensitivity and high
speciﬁcity. The optimal threshold value was determined by the
farthest point from the bisector of the ROC curve.
3. Results
3.1. Comparison of SNP frequencies between FCH patients and
controls
In order to identify differences between FCH patients and con-
trols, the genotype and allele frequencies were calculated and
compared. Dominant and recessive models for the rare allele were
also constructed to verify the association type of the variants.
The 1131T > C (rs662799) and S19W (rs3135506) variants in
the Apolipoprotein A-V gene (APOA5), 9996G > A (rs2073658) and
11235C > T (rs3737787) in the Upstream Stimulatory Factor 1 gene
(USF1) showed differences in frequencies (Table 3) while data
about frequencies of not statistically different SNPs are reported in
Supplemental Table 1.
The rare allele of both SNPs in APOA5 is more frequent in pa-
tients than in controls and is associated with the disease in a
dominant manner (i.e. if it is present in single or double copynumber) with an OR and 95% CI equal to 2.28 (1.33e3.91) for C
allele carriers of 1131T > C (rs662799) and to 2.51 (1.36e4.65) for
W allele carriers of S19W (rs3135506). Conversely, the rare allele of
both SNPs in USF1 is more frequent in healthy controls than in
patients, suggesting a protective role for these alleles in a dominant
manner. The presence of allele A for 9996G > A (rs2073658) and T
for 11235C > T (rs3737787) showed an OR and 95% CI of 0.45
(0.28e0.72) and 0.44 (0.28e0.70) respectively. Since the two vari-
ants in USF1 are almost completely in linkage (D0 ¼ 1), multivariate
regression analysis included only the rs2073658 SNP in order to
avoid the exclusion of both variants from the model.3.2. Association of SNPs with lipid parameters
In order to evaluate the association of SNPs to lipid values,
several linear regressions were performed including the dominant
model for the rare allele of SNPs 1131T > C (rs662799) and S19W
(rs3135506) in APOA5 and the 9996G > A (rs2073658) SNP in USF1,
Table 5
Beta-coefﬁcients and signiﬁcances obtained at multivariate logistic regression
analysis.
Independent variables Signiﬁcance Or 95% CI
APOA5 1131T > C p ¼ 0.018 11.03 1.52e80.06
APOA5 S19W ns 2.38 0.55e10.32
USF1 11235C > T ns 0.43 0.12e1.58
Age (years) ns 1.02 0.96e1.09
Male gender p ¼ 0.002 11.54 2.39e55.7
Total cholesterol (mmol/L) p < 0.0001 70.05 15.18e323.35
Triglycerides (mmol/L) p < 0.0001 23.01 6.46e81.91
BMI (kg/m2) ns 0.97 0.82e1.16
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APOA5 variants is associated with increased levels of total choles-
terol, triglycerides, non-HDL cholesterol, whereas only for S19W
(rs3135506) the rare allele is associated with increased LDL
cholesterol, LDL score and decreased mean LDL diameter and HDL
levels (Table 4) suggesting aworse lipid proﬁle of rare allele carriers
compared to non-carriers. On the other hand, the carriers of the
rare allele of 9996G > A (rs2073658) in USF1 showed decreased
levels of total cholesterol, triglycerides, non-HDL cholesterol, LDL
cholesterol, ApoB, ApoB/total cholesterol and LDL score and
increased levels of mean LDL diameter compared to homozygotes
for the common allele (Table 4), highlighting the protective role of
this variant.
3.3. Association of SNPs with FCH e risk evaluation
To test the association of the studied variants with FCH inde-
pendently of the other parameters commonly associated with the
disease, we performed a multivariate logistic regression including
the variants 1131T > C (rs662799) and S19W (rs3135506) in
APOA5 and the 9996G > A (rs2073658) in USF1, age, sex, BMI, total
cholesterol levels and triglycerides evaluated in the absence of
lipid-lowering drugs. SNP S19W (rs3135506) in APOA5 remains
signiﬁcantly associated with the presence of FCH independently of
the other factors with an OR of 11.03 (1.52e80.06) (Table 5). The
pseudo R-squared of this model is 0.83, indicating an improvement
of the full model compared to the intercept model and conﬁrming
the signiﬁcance of the selected parameters. To evaluate the ability
of FCH prediction based on the logistic regression model, we con-
structed a ﬁtted model, using the parameters above described, and
we performed a 10-fold cross-validation which was repeated 200
times. The logistic model performance can be assessed by the ROC
curve calculated for patients and controls on the basis of the ﬁtted
model (Fig. 1). The AUC is 0.987 and the optimal threshold of
probability to be classiﬁed as a FCH patient is 0.943 with a total
accuracy of 93.91%, a sensitivity of 94.22% and a speciﬁcity of
93.54%.
4. Discussion
Twenty SNPs in genes involved in lipid metabolism have been
studied in relation to the presence of FCH. We show that the fre-
quencies of variants 1131T > C (rs662799) and S19W (rs3135506)
in APOA5, and of variants 9996G > A (rs2073658) and 11235C > TTable 4
Beta-coefﬁcients and signiﬁcances obtained at multivariate linear regression analysis pe
Independent variables Total cholesterol Triglycerides N
b Signiﬁcance b Signiﬁcance b
APOA5 -1131T > C 0.388 p ¼ 0.050 0.468 p ¼ 0.028
APOA5 S19W 0.663 p ¼ 0.003 0.746 p ¼ 0.002
USF1 9996G > A 0.485 p ¼ 0.005 0.470 p ¼ 0.012 
Age 0.031 p < 0.0001 0.013 ns
Male gender 0.291 ns 0.817 p < 0.0001
BMI 0.048 p ¼ 0.040 0.085 p ¼ 0.001
Independent variables LDL score Mean LDL diameter
b Signiﬁcance b Sign
APOA5 -1131T > C 2.155 ns 1.027 ns
APOA5 S19W 7.653 p ¼ 0.0003 3.396 p ¼
USF1 9996G > A 4.848 p ¼ 0.003 2.033 p ¼
Age 0.281 p ¼ 0.0003 0.115 p ¼
Male gender 7.152 p < 0.0001 3.754 p <
BMI 0.401 ns 0.202 p ¼
ns ¼ not signiﬁcant.(rs3737787) in USF1 differ between patients and control subjects.
Patients bearing the rare allele of both SNPs in APOA5 and the
homozygotes for the common allele of both SNPs in USF1 had a
higher risk of FCH compared to carriers of the other genotypes.
These data have been obtained in a well selected population in
which the presence of gene defects causing other dyslipidemias
with a similar phenotype was excluded as recommended in the
diagnostic procedures [4]. The presence of LDLRmutations or of the
E2/E2 genotype was an exclusion criterion, whereas this exclusion
criterionwas not applied inmost of the previous studies. Since each
SNP accounts for a tiny part of the dyslipidemic phenotype, the
presence of a more relevant variant could mask the role of the SNPs
studied herein.
After the ﬁrst evidence of linkage between USF1 variants and
FCH [13], various studies have conﬁrmed the protective role of the
rare allele of USF1 SNPs in different populations of FCH patients
[14e16]. Here we report the ﬁrst evidence of an association of USF1
variants in an Italian population affected by FCH. Linear regression
analysis showed that the presence of the SNPs in APOA5 andUSF1 is
directly associated to the lipid levels, which indicates that these
various play a role in phenotype development, and partially explain
its lipid variability. In particular, carriers of the rare allele of both
SNPs in APOA5 and homozygotes of the common allele of 9996G> A
(rs2073658) in USF1 had a worse lipid proﬁle compared to carriers
of other genotypes. The association of both 9996G > A (rs2073658)
and 11235C > T (rs3737787) in USF1 with triglyceride levels was
previously reported in FCH patients [14,17,18] as well as in patients
with cardiovascular disease [19], carotid artery intima-media
thickness [20], type 2 diabetes [21] or obesity [22].
It was recently demonstrated that the rare allele of USF1
9996G > A (rs2073658) induces FOXOA expression less efﬁciently
than the common allele, thereby leading to a minor expression ofrformed using different lipid parameters as dependent variable.
on-HDL cholesterol HDL cholesterol LDL cholesterol
Signiﬁcance b Signiﬁcance b Signiﬁcance
0.425 p ¼ 0.035 0.035 ns 0.211 ns
0.780 p ¼ 0.001 0.114 p ¼ 0.008 0.439 p ¼ 0.025
0.536 p ¼ 0.002 0.053 ns 0.328 p ¼ 0.032
0.032 p ¼ 0.0001 0.000 ns 0.025 p ¼ 0.0005
0.582 p ¼ 0.002 0.287 p < 0.0001 0.236 ns
0.072 p ¼ 0.003 0.023 p < 0.0001 0.036 ns
ApoB ApoB/total cholesterol
iﬁcance b Signiﬁcance b Signiﬁcance
0.048 ns 0.002 ns
0.000 0.061 ns 0.007 ns
0.003 0.147 p ¼ 0.0002 0.008 p ¼ 0.028
0.001 0.008 p < 0.0001 0.000 p ¼ 0.034
0.0001 0.083 p ¼ 0.045 0.007 p ¼ 0.071
0.032 0.011 p ¼ 0.040 0.000 ns
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Fig. 1. ROC curve of probabilities of having FCH calculated by a 10-fold cross-validation
repeated 200 times The curve describes the variation of sensitivity and speciﬁcity
obtained with each value of probability of having FCH. The arrow indicates the optimal
threshold (i.e. the point farthest from the bisector of the ROC curve).
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poration of triglycerides into VLDL [22] and their secretion. How-
ever, other studies report conﬂicting results regarding the role of
the rare allele of USF1 9996G > A (rs2073658). In fact, the minor
allele of this SNP was often considered the risk allele [19,23e25],
while other did not ﬁnd an association between the minor allele
and the disease [26].
Different inclusion criteria for FCH cases or the lack of appro-
priate control groups (i.e., absence of family history of dislipidemia,
medical history based on questionnaires, etc.), together with the
speciﬁc ethnic characteristics of the populations examined, may
explain these discordant ﬁndings. The absence of an association of
the other studied SNPs with the disease could be explained in the
same way. In light of the above considerations, further studies are
needed to provide unbiased information for SNP selection.
Several studies of the association of the e1131T > C (rs662799)
and S19W (rs3135506) SNPs in the APOA5 gene with FCH found
that FCH patients more frequently carried variants rs662799 [27],
rs3135506 [26,28] or both [29,30] compared to controls. The as-
sociation of the rare allele of both SNPs with increased triglyceride
levels was also demonstrated in other studies [26,28,30e32]. Zheng
at al [33]. observed that most of the studies evaluating the associ-
ation of APOA5 SNPs with metabolic syndrome or its components
lacked the correction for triglyceride levels or that the association
disappeared after this correction.
In our study, logistic regression analysis showed that also after
correction for BMI, age, sex, cholesterol and triglyceride levels, the
S19W polymorphism in APOA5 remained signiﬁcantly associated
with the presence of the disease. This result highlights that this SNP
plays an important role in the identiﬁcation of subjects at risk of
developing FCH. The diagnosis of FCH is still difﬁcult due to the
need for repeated measurements of cholesterol and triglyceride
levels that have a high biological variability. In addition, lipid levels
are increased in different dyslipidemias, including non-familial or
secondary dyslipidemias. As the genotype is a permanent factorthat is not inﬂuenced by such biological variability as biochemical
factors, the typing of an SNP may help to select patients at a high
risk of FCH.
The association of 1131T > C (rs662799) and S19W
(rs3135506) in APOA5, and of 9996G > A (rs2073658) in USF1 with
anthropometric factors and cholesterol and triglyceride levels is
demonstrated by the high value of the pseudo R-squared obtained
at the logistic regression and conﬁrmed by the cross-validation
analysis. Using the probabilities calculated with the ﬁtted model
obtained through a cross-validation analysis, we constructed a ROC
curvewith an AUC of 0.987, indicating a good ability to discriminate
patients from controls. Using the results of a multivariate logistic
regression, Veerkamp et al. [34] constructed a Nomogram based on
biochemical measurements to calculate the probability of FCH. Our
model includes the genetic variants together with biochemical and
anthropometric factors to calculate FCH risk and the resulting
threshold of 0.943 shows an accuracy of 93.91% with a sensitivity of
94.22% and a speciﬁcity of 93.54%.
5. Study limitations
A limitation of this study is the small sample size, which may
diminish the relevance of our conclusions. Although the fre-
quencies of the APOA5 19W and 1131C alleles are rather low, our
results were obtained in a well selected population. In fact, the
presence of gene defects causing other dyslipidemias with a similar
phenotype was excluded. Another limitation of the study is the
selection of SNP, since we typed the SNPs most frequently associ-
ated to dyslipidemia. In particular, we did not examine the
involvement of other SNPs such as rs2516839 in USF1 which is
associated to high triglyceride levels and atherosclerosis [32]. More
extensive investigations are required to verify and extend our data.
6. Conclusions
Our results show that USF1 and APOA5 polymorphisms are
associated with FCH and that the S19W SNP (rs3135506) in the
APOA5 gene is associated to the disease independently of total
cholesterol, triglycerides and BMI.
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